Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease

被引:15
|
作者
Schumacher, Julia [1 ,2 ,12 ]
Kanel, Prabesh [3 ,4 ,5 ]
Dyrba, Martin [1 ]
Storch, Alexander [1 ,2 ]
Bohnen, Nicolaas, I [3 ,4 ,5 ,6 ,7 ,8 ]
Teipel, Stefan [1 ,9 ]
Grothe, Michel J. [10 ,11 ,13 ]
机构
[1] Deutsch Zentrum Neurodegenerat Erkrankungen DZNE R, D-18147 Rostock, Germany
[2] Univ Med Ctr Rostock, Dept Neurol, D-18147 Rostock, Germany
[3] Univ Michigan, Morris K Udall Ctr Excellence Parkinsons Dis Res, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Parkinsons Fdn Res Ctr Excellence, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Radiol, Ann Arbor, MI 48105 USA
[6] Vet Adm Ann Arbor Healthcare Syst, Neurol Serv, Ann Arbor, MI 48105 USA
[7] Vet Adm Ann Arbor Healthcare Syst, GRECC, Ann Arbor, MI 48105 USA
[8] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA
[9] Univ Med Ctr Rostock, Dept Psychosomat Med, D-18147 Rostock, Germany
[10] Univ Seville, Hosp Univ Virgen Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,CSIC,Inst Biomed Sevi, Seville 41013, Spain
[11] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid 28031, Spain
[12] Deutsch Zentrum Neurodegenerat Erkrankungen DZNE, Gehlsheimer Str 20, D-18147 Rostock, Germany
[13] Hosp Univ Virgen Rocio, Inst Biomed Sevilla, Unidad Trastornos Movimiento, Avda Manuel Siurot S-N, Seville 41013, Spain
关键词
basal forebrain; Parkinson's disease; MRI; positron emission tomography; acetylcholinesterase; cholinergic deficit; BASAL FOREBRAIN ATROPHY; ALZHEIMERS-DISEASE; NUCLEUS BASALIS; LEWY BODIES; IMPAIRMENT; DEMENTIA; DENERVATION; DEFICITS; MEMORY;
D O I
10.1093/brain/awad226
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cognitive decline in Parkinson's disease is related to cholinergic system degeneration, which can be assessed in vivo using structural MRI markers of basal forebrain volume and PET measures of cortical cholinergic activity. In the present study we aimed to examine the interrelation between basal forebrain degeneration and PET-measured depletion of cortical acetylcholinesterase activity as well as their relative contribution to cognitive impairment in Parkinson's disease.This cross-sectional study included 143 Parkinson's disease participants without dementia and 52 healthy control participants who underwent structural MRI, PET scanning with 11C-methyl-4-piperidinyl propionate (PMP) as a measure of cortical acetylcholinesterase activity, and a detailed cognitive assessment. Based on the fifth percentile of the overall cortical PMP PET signal from the control group, people with Parkinson's disease were subdivided into a normo-cholinergic (n = 94) and a hypo-cholinergic group (n = 49). Volumes of functionally defined posterior and anterior basal forebrain subregions were extracted using an established automated MRI volumetry approach based on a stereotactic atlas of cholinergic basal forebrain nuclei. We used Bayesian t-tests to compare basal forebrain volumes between controls, and normo- and hypo-cholinergic Parkinson's participants after covarying out age, sex and years of education. Associations between the two cholinergic imaging measures were assessed across all people with Parkinson's disease using Bayesian correlations and their respective relations with performance in different cognitive domains were assessed with Bayesian ANCOVAs. As a specificity analysis, hippocampal volume was added to the analysis.We found evidence for a reduction of posterior basal forebrain volume in the hypo-cholinergic compared to both normo-cholinergic Parkinson's disease [Bayes factor against the null model (BF10) = 8.2] and control participants (BF10 = 6.0), while for the anterior basal forebrain the evidence was inconclusive (BF10 < 3). In continuous association analyses, posterior basal forebrain volume was significantly associated with cortical PMP PET signal in a temporo-posterior distribution. The combined models for the prediction of cognitive scores showed that both cholinergic markers (posterior basal forebrain volume and cortical PMP PET signal) were independently related to multi-domain cognitive deficits, and were more important predictors for all cognitive scores, including memory scores, than hippocampal volume.We conclude that degeneration of the posterior basal forebrain in Parkinson's disease is accompanied by functional cortical changes in acetylcholinesterase activity and that both PET and MRI cholinergic imaging markers are independently associated with multi-domain cognitive deficits in Parkinson's disease without dementia. Comparatively, hippocampal atrophy only seems to have minimal involvement in the development of early cognitive impairment in Parkinson's disease.
引用
收藏
页码:4964 / 4973
页数:10
相关论文
共 50 条
  • [41] Imaging Markers of Progression in Parkinson's Disease
    Strafella, Antonio P.
    Bohnen, Nico I.
    Pavese, Nicola
    Vaillancourt, David E.
    van Eimeren, Thilo
    Politis, Marios
    Tessitore, Alessandro
    Ghadery, Christine
    Lewis, Simon
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2018, 5 (06): : 586 - 596
  • [42] Cognitive decline in Parkinson's disease as measured by the Montreal cognitive assessment
    Rice, T. C.
    Riley, D. E.
    Walter, E. M.
    Whitney, C. M.
    Walter, B. L.
    Gunzler, S. A.
    MOVEMENT DISORDERS, 2011, 26 : S160 - S160
  • [43] Effect of cholinergic modulator in Parkinson's disease with cognitive impairment
    Aman, Yahyah
    NATURE AGING, 2025, 5 (02): : 177 - 177
  • [44] Magnetic Resonance Imaging Markers for Cognitive Impairment in Parkinson's Disease: Current View
    Hou, Yanbing
    Shang, Huifang
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [45] Test for Alzheimer's disease predicts cognitive decline in Parkinson's disease
    不详
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2012, 27 (01): : 77 - 77
  • [46] Predicting cognitive decline in older people by structural and molecular imaging
    Teipel, Stefan
    Tang, Yi
    Boccardi, Marina
    CURRENT OPINION IN NEUROLOGY, 2023, 36 (04) : 253 - 263
  • [47] Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
    Lim, Nicholas S.
    Swanson, Christine R.
    Cherng, Hua-Ren
    Unger, Travis L.
    Xie, Sharon X.
    Weintraub, Daniel
    Marek, Ken
    Stern, Matthew B.
    Siderowf, Andrew
    Trojanowski, John Q.
    Chen-Plotkin, Alice S.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2016, 3 (05): : 346 - 355
  • [48] Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2)
    Yousaf, Tayyabah
    Pagano, Gennaro
    Niccolini, Flavia
    Politis, Marios
    JOURNAL OF NEUROLOGY, 2019, 266 (05) : 1203 - 1210
  • [49] Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication
    Reyes-Perez, Paula
    Bandres-Ciga, Sara
    MOVEMENT DISORDERS, 2021, 36 (11) : 2506 - 2507
  • [50] Predicting cognitive decline with non-clinical markers in Parkinson’s disease (PRECODE-2)
    Tayyabah Yousaf
    Gennaro Pagano
    Flavia Niccolini
    Marios Politis
    Journal of Neurology, 2019, 266 : 1203 - 1210